Division of Pharmacognosy, Department of Medicinal Resources, Institute of Natural Medicine, University of Toyama, 2630, Sugitani, Toyama, 930-0194, Japan.
Pharmaceutical Affairs Division, Health and Welfare Department of Nagano Prefecture, 692-2, Habashita, Minaminagano, Nagano, 380-8570, Japan.
J Nat Med. 2019 Jun;73(3):541-554. doi: 10.1007/s11418-019-01298-4. Epub 2019 Apr 5.
In order to develop new domestic production of Rhei Rhizoma (RR) from Rheum specimens cultivated in the Sugadaira Medicinal Plant Cultivation Test Field (SMPCF), the ITS sequences of 12 SMPCF specimens and Chinese Rheum specimens of four species, as well as RR samples produced in North Korea, China and Japan, were determined by subcloning and their sequences were compared. As the ITS sequences of 10 SMPCF specimens showed significant intra-individual polymorphism, identification of pseudogenes was conducted by detecting the three motifs of the 5.8S sequence and the stability of the 5.8S secondary structure. Approximately 46% of sequences obtained from the SMPCF specimens were putative pseudogenes. The maximum likelihood tree based on ITS sequences showed three main groups-the outer group and inner clusters I and II; clones from 10 SMPCF specimens including putative pseudogenes belonged to the outer group. Cluster I was composed of two clades, one including clones from R. officinale specimens and R. palmatum-derived samples with matK genotype Rp9, and another including clones from R. coreanum-derived samples. Cluster II consisted of three clades, one including clones from R. palmatum specimens with genotype Rp5, another including clones mainly from R. tanguticum specimens with genotype Rt4, and the third including clones from R. palmatum or R. tanguticum specimens with various matK genotypes. Clones from SMPCF specimen RC5 showed a close relationship with those from R. tanguticum specimens with matK genotype Rt4, whereas those from specimen RC9 related to R. coreanum-derived samples. As a result, specimens RC5 and RC9 were considered as candidates for the development of domestic RR.
为了从菱泽药用植物栽培试验场(SMPCF)种植的大黄属植物标本中开发国产大黄(RR),通过亚克隆确定了 12 个 SMPCF 标本和 4 种中国大黄属植物的 ITS 序列,以及来自朝鲜、中国和日本的 RR 样品,并对其序列进行了比较。由于 10 个 SMPCF 标本的 ITS 序列表现出显著的个体内多态性,通过检测 5.8S 序列的三个基序和 5.8S 二级结构的稳定性来检测假基因。从 SMPCF 标本中获得的大约 46%的序列是假定的假基因。基于 ITS 序列的最大似然树显示了三个主要组-外组和内群 I 和 II;来自 10 个 SMPCF 标本的克隆,包括假定的假基因,属于外组。群 I 由两个分支组成,一个分支包括来自 R. officinale 标本和具有 matK 基因型 Rp9 的 R. palmatum 衍生样品的克隆,另一个分支包括来自 R. coreanum 衍生样品的克隆。群 II 由三个分支组成,一个分支包括具有基因型 Rp5 的 R. palmatum 标本的克隆,另一个分支包括主要来自 R. tanguticum 标本的具有基因型 Rt4 的克隆,第三个分支包括具有各种 matK 基因型的 R. palmatum 或 R. tanguticum 标本的克隆。来自 SMPCF 标本 RC5 的克隆与具有 matK 基因型 Rt4 的 R. tanguticum 标本的克隆密切相关,而来自标本 RC9 的克隆与 R. coreanum 衍生的样品有关。因此,将标本 RC5 和 RC9 视为开发国产 RR 的候选者。